Hepatitis B

World Hepatitis Day is observed annually on July 28 to raise awareness of this infectious disease and its impact on global health. The primary goal is to promote hepatitis prevention and show support

India accounted for the second-highest number of cases of hepatitis B and C in 2022 after China, with 3.5 crore infections, according to a report by the World Health Organisation (WHO). Hepatitis is an inflammation of the liver that can cause a range of health problems and can be fatal. According to the WHO's 2024 Global Hepatitis Report released on Tuesday, 254 million people lived with hepatitis B and 50 million with hepatitis C in 2022 globally. India, which was second only to China in the viral hepatitis burden, registered 2.98 crore hepatitis B cases in 2022 while the number of hepatitis C infections stood at 55 lakh. China registered 8.3 crore cases of hepatitis B and C, representing 27.5 per cent of the total disease burden. The report said that with a total of 3.5 crore cases, India accounted for 11.6 per cent of the total disease burden globally that year. There are five main strains of the hepatitis virus, referred to as types A, B, C, D and E. While they all cause live

World Hepatitis Day aims to raise awareness about viral hepatitis and finding ways to prevent, test and treat the disease. Reports say someone dies every 30 seconds globally due to hepatitis

While widespread screening is being conducted, health department representatives informed that 37 people have tested positive for hepatitis A virus in North Guwahati

Three doses of HEPLISAV-B vaccine provide full protection to adults with HIV, who were never immunised against hepatitis B virus (HBV) either through vaccination or infection, according to a study. In the research presented at the annual IDWeek conference held in Washington, US from October 19 to 23, the researchers from University of Cincinnati and Cornell University tested the three-dose course of HEPLISAV-B among 68 adults living with HIV at 38 sites in the US, South Africa, and Thailand. None of the participants had either received a previous HBV vaccination or had evidence of a previous HBV infection - all were on antiretroviral therapy to combat infection by retroviruses such as HIV. Retroviruses are a group of viruses that contain two single-strand linear RNA molecules per virion, or a viral particle, and reverse transcriptase (RNA to DNA). Following the initial dose of HEPLISAV-B vaccine 0.5 milliliter (mL) as an intramuscular injection, the study participants received ...

Health officials around the world are investigating a mysterious increase in cases of the liver condition which was first spotted in the UK

A senior government official had told Business Standard last week that so far there was no scientific evidence to expand the vaccination programme to young children

A recent spate of severe liver inflammation (hepatitis) has been reported in previously healthy children. As of April 21, there have been 169 confirmed cases of acute hepatitis of unknown origin

What is Hepatitis B, what are its symptoms, treatment and how to prevent Hepatitis B - these are some of the questions we'll be answering

BS ReporterHyderabad, 23 October: Hyderabad-based Laurus Labs Limited today announced that it has transferred an abbreviated new drug application(ANDA) of Tenofovir Disoproxil Fumarate (TDF) to Nasdaq-listed biopharmaceutical company CASI Pharmaceuticals for use in China, in exchange for certain up-front and milestone payments. Laurus Lab's new drug application of TDF was approved by the US Food and Drug Administration(US FDA).TDF is prescribed for the treatment of Hepatitis B virus(HBV) infection. China is expected to have more than 90 million chronic carriers of hepatitis B, roughly one-third of all HBV cases in the world. TDF is used as the first line of therapy."The transfer of TDF ANDA for its use in China enhances our strategic focus to leverage our development and manufacturing capabilities in the markets where we have little presence. Partnering with CASI Pharmaceuticals, in particular, would enable Laurus Labs to monetise its asset in China while building a robust pipeline ...